Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

May 2, 2020

Primary Completion Date

October 17, 2020

Study Completion Date

October 17, 2020

Conditions
Cytokine Storm (Covid-19)
Interventions
DRUG

Ruxolitinib

Ruxolitinib 5 mg tablets

DRUG

Placebo

Matching-image placebo

Trial Locations (61)

1

Novartis Investigative Site, Lima

10

Novartis Investigative Site, Lima

27

Novartis Investigative Site, San Isidro

32

Novartis Investigative Site, San Miguel

10461

Novartis Investigative Site, The Bronx

14050

Novartis Investigative Site, Mexico City

14080

Novartis Investigative Site, Mexico City

23538

Novartis Investigative Site, Lübeck

28031

Novartis Investigative Site, Madrid

28034

Novartis Investigative Site, Madrid

30312

Novartis Investigative Site, Atlanta

33604

Novartis Investigative Site, Pessac

34098

Novartis Investigative Site, Istanbul

35110

Novartis Investigative Site, Yenisehir/Izmir

37007

Novartis Investigative Site, Salamanca

44093

Novartis Investigative Site, Nantes

48109

Novartis Investigative Site, Ann Arbor

52787

Novartis Investigative Site, Estado de México

69495

Novartis Investigative Site, Pierre-Bénite

75149

Novartis Investigative Site, Mesquite

80045

Novartis Investigative Site, Aurora

80205

Novartis Investigative Site, Denver

81377

Novartis Investigative Site, München

83404

Novartis Investigative Site, Idaho Falls

90419

Novartis Investigative Site, Nuremberg

92701

Novartis Investigative Site, Colombes

92835

Novartis Investigative Site, Fullerton

95600

Novartis Investigative Site, Eaubonne

98104

Novartis Investigative Site, Seattle

111539

Novartis Investigative Site, Moscow

123056

Novartis Investigative Site, Moscow

193312

Novartis Investigative Site, Saint Petersburg

194044

Novartis Investigative Site, Saint Petersburg

194354

Novartis Investigative Site, S-Petersburg

197706

Novartis Investigative Site, Sestroretsk

199106

Novartis Investigative Site, Saint Petersburg

390039

Novartis Investigative Site, Ryazan

656045

Novartis Investigative Site, Barnaul

89030101

Novartis Investigative Site, Blumenau

07103

Novartis Investigative Site, Newark

53705-3611

Novartis Investigative Site, Madison

CP1405

Novartis Investigative Site, C A B A

C1426AAM

Novartis Investigative Site, Buenos Aires

C1430BKC

Novartis Investigative Site, Buenos Aires

22640-000

Novartis Investigative Site, Rio de Janeiro

14784 400

Novartis Investigative Site, Barretos

01327 001

Novartis Investigative Site, São Paulo

04502 001

Novartis Investigative Site, São Paulo

Unknown

Novartis Investigative Site, Sorocaba

Novartis Investigative Site, Barranquilla

Novartis Investigative Site, Istanbul

054047

Novartis Investigative Site, Rionegro

080005

Novartis Investigative Site, Barranquilla

08916

Novartis Investigative Site, Badalona

08035

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara

HA1 3UJ

Novartis Investigative Site, Harrow

LS9 7TF

Novartis Investigative Site, Leeds

SE5 9RS

Novartis Investigative Site, London

WC1E 6HX

Novartis Investigative Site, London

M13 9PL

Novartis Investigative Site, Manchester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY